TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06559943

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Physiotherapy + Placebo Kinesio Tape
Description: Following a total of 15 sessions of electrophysical agent and exercise training, 5 days a week, for 3 weeks, each session lasting 45 minutes, followed by traditional physiotherapy, 2 days a week, for 3 weeks, a total of 6 times, with 0% tension applied to the trapezius muscle in the neck region (I). Kinesiotape will be applied.~The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method
Description: In addition to a total of 15 sessions of electrophysical agents and exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, kinesio tape will be applied 6 times in total, 2 days a week. Kinesiotape will be cut into an (I) shape (15 cm) with 50% tension and adhered laterally to the C7 joint. In acute cases such as overuse and muscle spasm, it is recommended to apply an inhibition technique that will inhibit the muscle. In the inhibition technique, the direction of the tape should be from the entry point of the muscle to the starting point and the application should be done with very light or light (15 - 25%) tension. In chronic cases, a facilitation technique should be applied to stimulate the weak muscle. The direction of the tape should be from the starting point of the muscle to the attachment point and the application should be done with light or moderate tension (25 - 50%).
Study: NCT05667779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRL-101
Description: Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo comparator will be administered at all dose levels.
Study: NCT05480020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 toothpaste
Description: Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 toothpaste
Description: Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 toothpaste
Description: Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.
Study: NCT04848883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced AMS program
Description: 1. - Telephone acces to infectious disease experts to discuss patients' therpies during working days.~2. - Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard AMS program
Description: 1. - Educational materials.~2. - Updated local antibiotic guidelines.~3. - Promotion of delayed antibiotic prescription.~4. - Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. - Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. - Quarterly reports to prescribers of AMS outcomes at the centre-level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard AMS program
Description: 1. - Educational materials.~2. - Updated local antibiotic guidelines.~3. - Promotion of delayed antibiotic prescription.~4. - Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. - Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. - Quarterly reports to prescribers of AMS outcomes at the centre-level.
Study: NCT06391216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052 and Bifidobacterium longum R0175
Description: 8-week supplementation (56 days); 3 × 10\^9 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8-week supplementation (56 days)
Study: NCT05582096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3457263
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT06436937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single meal containing 20 g of 15N intrinsically labelled protein from honey chlorella
Description: Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single meal containing 20 g of 15N intrinsically labelled protein from faba bean meat analogue
Description: Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
Study: NCT05559853

Intervention type: DIAGNOSTIC_TEST
Intervention: CEST-MRF
Description: CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.

Intervention type: DIAGNOSTIC_TEST
Intervention: CEST-MRF
Description: CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
Study: NCT04511416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR, 500-2000mg nocte
Description: Metformin XR, 500-2000mg nocte

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR, 500-2000mg nocte
Description: Metformin XR, 500-2000mg nocte
Study: NCT06347029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling
Study: NCT04959760

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.
Description: The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
Study: NCT06493136

Intervention type: DRUG
Intervention: lidocaine gel
Description: questionnaire
Study: NCT04875832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing - EMDR
Description: EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences
Study: NCT05493384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
Study: NCT06358911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly amido amine dendrimer (PAMAM)
Description: Desensitizing agents was applied once after the bleaching procedure,as follows:~1-Bleaching/PAMAM group, patients received bleaching followed by the application of PAMAM for 30 minutes according to previous studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manufacturer's desensitizing agent, Ultra EZ
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI paste plus, desensitizing agent
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and F (ReminPro), desensitizing agent
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes
Study: NCT06390514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibrating floor
Description: activities with vibrating floor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No vibrating floor
Description: activities without vibrating floor
Study: NCT05826015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: IV over 60 minutes
Study: NCT06076356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam Rolling
Description: Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
Study: NCT06056622

Intervention type: OTHER
Group type: OTHER
Intervention: Combined Exercises
Description: The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Exercise
Description: Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
Study: NCT04975750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving intervention
Description: The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
Study: NCT04811612

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Warmed heel stick
Description: One heel will be warmed before sampling with the other heel will not be warmed
Study: NCT06085963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ITULAZAX 12 SQ-Bet
Description: Active ingredients: Birch (Betula verrucosa) extracts Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Dose/strength: 12 SQ-Bet Excipients: Gelatine (fish source), mannitol and sodium hydroxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Active ingredients: None Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Excipients: Gelatine (fish source), mannitol and sodium hydroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nacl
Description: Sodium chloride solution 9mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl
Description: Sodium chloride solution 9mg/ml
Study: NCT05230342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A package containing a mix of functional foods
Description: Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ingredient group
Description: The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
Study: NCT05702242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD removal with no visible strings
Description: Removal with either alligator forceps or MVA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD removal with no visible strings
Description: Removal with either alligator forceps or MVA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alligator forceps
Description: IUD removal with alligator forceps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspirator
Description: IUD removal with MVA
Study: NCT05222035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
Study: NCT05266014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinlarebant
Description: Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months.
Study: NCT04902417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy Foods (Yoghurt, Cheese, Milk)
Description: Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
Study: NCT05401110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab
Description: Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Study: NCT06584396

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05523011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exosome ointment
Description: 100 µg MSC exosomes/g ointment
Study: NCT05070988

Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
Study: NCT05723913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: A package containing a mix of functional foods
Description: Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
Study: NCT04828226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
Study: NCT06503783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05710991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Workshop
Description: Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia Workshop
Description: The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
Study: NCT06648070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular reeducation technique
Description: 5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
Study: NCT05969223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab
Description: Subcutaneous injection
Study: NCT05169437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Eligible participants will receive daily dosing of Niraparib.
Study: NCT06344351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3006 tablets
Description: TQB3006 is an inhibitor protein.
Study: NCT04863781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile cognitive-behavioral stress management intervention
Description: Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.